“We have the evidence”

12:13 p.m. EST:

The link, located here is an interview with Reiner Fuellmich, a lawyer (a good one) that’s been at the center of the ‘speck’ investigation since inception.

This one interview, all nineteen-minutes, thirty one seconds, is probably the best summary of the current situation.

The link above comes with a warning:

If you’re one of those still asleep, after watching the interview, you’ll never be the same. You’ll be forever changed.

To put it biblically, “Your eyes will be opened”.

That is, if this lie can be perpetrated world-wide (as it has), then what does that say about all other media generated propaganda: the (stolen) election, the fake oval office, the fake executive orders, the fake insurrection.

The examples above are just from the past six-months!

For emphasis, we’ll throw in one more link that seems un-related but it’s not; it shows just how long events have been purposely shaped to fit a narrative.

Of course, this ‘thought shaping’ goes back even farther … if not a hundred years or more.

Market Impact:

So, what’s all this have to do with the markets and specifically biotech, IBB?

The interview’s implications for biotech are clear.

David Stockman has a post located here whose title sums it up nicely:

‘… a scam like no other’.

It’s just a matter of time before the public is either awakened or severely, permanently, damaged by following (and believing) the lie.

This time around, cemeteries are likely to be overrun … for real.

If that happens, repercussions to the biotech sector would (likely) be severe to catastrophic (down -90%, maybe?).

Even though a few within IBB are directly involved, all are likely to take a hit

Market Positioning:

In our Project Stimulus table, we’re short biotech via LABD (not advice, not a recommendation). The stop has been moved above break-even.

It’s important to not let fundamentals (above) bleed into market positioning. It’s impossible to say when or if fundamentals will take control.

What we have now is IBB looking as if those fundamentals are providing a backdrop for technical action (described below). However, technical action can change instantly.

Biotech, IBB Technical Analysis:

Typically, this morning’s action would signal a ‘short exit’ or ‘go long’; when price action immediately gaps above the prior session high.

However, we already know on a long term (quarterly, monthly, weekly) basis, IBB has reversed. That does not mean price can’t go into some type of truncated rally … it can.

What the long term momentum says, if a rally occurs, it’s likely to be short and reverse quickly.

As of this post, it looks like whatever rally there was, it was over within the hour.

Technically, we have an interesting situation. IBB may have formed an Andrews’ Pitchfork.

The first chart shows the set up and has the width of the Pitchfork at a Fibonacci 21-days (plus one).

The second chart is a compressed version for better perspective.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Pre-Market

9:13 a.m. EST: Since the ‘project’s’ positioned short biotech, that’s the focus for the morning.

The last two updates, here and here, showed biotech acting differently than other markets.

With IBB currently down nearly -15%, from its all time print high, it’s already in ‘correction’ territory; just a few percent more, it’ll be classified as ‘bear market’.

The weekly close shows another bearish set-up with what looks like a Head & Shoulders pattern. Note the second ‘bounce’ off the neckline was markedly lower than the first.

Energy to the upside is dissipating. Price action may be ready to penetrate the neckline.

As of this post, inverse fund LABD is trading unchanged to slightly higher (on about 24,000 shares).

If there’s a decisive move lower in IBB (higher LABD), we’ll change the LABD stop. With a current stop at 22.96, (not advice, not a recommendation) we’re right at break even.

Truth Begins to Surface

Stated many times on this site, with such a big (world-wide) lie, it’ll be hard to keep the truth under wraps … especially so, when scenes like this are everyday events.

Several corporations in the IBB sector, are providing the public ‘service’ shown in the above link. We’ll go into their technical condition in a separate update.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech … Down, Down, Down

Momentum:

Monthly, weekly and daily MACD histogram, all down.

We’ll look at several daily charts before moving on to weekly and P&F.

Above, the Head & Shoulders pattern is clear. There’s a down-sloping neckline with a rally that looks to be rolling over.

An alternate view are two wedge patterns:

On to the weekly. A Fibonacci projection has been added showing down move potential.

Lastly, daily P&F with its own projections.

Interesting to note: Range from 104 – 127, closely matches the 100.0% – 161.8%, Fibonacci range of 108.50 – 128:

From the previous update, biotech IBB, appears to have broken from the crowd. Momentum indicators on multiple timeframes have all lined up to the downside.

Friday’s after-market activity (BigCharts), has IBB down -0.84, on a solid 1,035,712, shares.

If the aftermarket volume is correct (no misprints or errors), it’s equivalent to 25% , of the entire volume for the day’s regular session.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Print High & Close

The table lists well known index ETF’s; along with most recent highs and current (Friday) close:

All the usual suspects are there:

S&P 500, SPY, The Dow 30, DIA, Nasdaq, QQQ, and on.

What’s also listed is how far each index (ETF) is from its most recent all time high or ‘recovery’ high (in percentage terms).

Obviously, one of these is completely out of bed: Biotech, IBB

We’ll be discussing the technical condition of biotech tomorrow. For now, the updated ‘project’ chart’s included below:

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech: Before The Open

9:02 a.m., EST:

Decisive trend break and test. Biotech IBB’s, ready to continue downside action.

Today may be the day for downside follow-through. We’ll see.

The work has already been done showing long term IBB, has reversed to the downside. Reference posts here and here, if needed.

The hourly chart of inverse fund LABD (3X inverse, IBB) shows pre-market range along with potential trend activity.

Yesterday, IBB was shorted via LABD (not advice, not a recommendation). Project table below:

If and when IBB makes a new daily low and LABD a new daily high, the stop will be moved. If so, the GTC stop order is likely to be updated toward the end of the session.

As this post is being created, Bid/Ask spreads on LABD are fluctuating.

Last trade @ 23.31 +0.23, +1.00%. Earlier, pre-market trading was lower.

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Position Change

DRV pushed through our stop early in the session; position closed (not advice, not a recommendation).

1:50 p.m. EST:

Despite all the analysis, IYR is showing continued buoyancy.

Something else is going on; possibly related to Uneducated Economist’s link provided in the last update.

Taking his cue, a functioning mortgage market is all important to the financial narrative, it’s possible this market will be more heavily manipulated than others.

At this juncture it would make sense. All indications are for reversal … yet it’s not happening in any significant way.

Time for another trade.

We’re going back to a market that in retrospect, should’ve been the focus all along; Biotech.

This site’s coming from the perspective those reading, are well aware the ‘speck’ as we call it (to avoid censorship) was a fabricated event.

Just a reminder that we’re not some ‘Johnny come lately’, here’s the link from way back in May, last year.

That post proves the situation was figured out well before the May 17th publish date (interviews, observations conducted a month prior).

What’s not fabricated however, are the repercussions from the so-called cure for the speck.

Unfortunately, those are happening now and are quite real.

Moving on to the trade.

Despite the number of transactions shown in the Project Stimulus table (below), the objective is to minimize activity. We’re looking for a mid, to long term sustainable move; gain potential, 100% to 1,000%.

Updated previously, very long term (Quarterly) IBB has reversed.

Monthly and weekly have reversed as well; both the monthly and weekly MACD indicators point down. Daily is essentially flat.

The hourly chart of LABD (3X inverse IBB) shows the entry location and subsequent price action. Stop is the session low @ 22.23 (not advice, not a recommendation).

It’s worth repeating, the false narrative on the speck and consequences of speck protection may blow up in the media (and biotech) at any time.

As J.P. says, getting people to do something they know is bad for them (or lethal) is the ultimate ‘elite’ high.

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Something Different, Biotech

A long term (Quarterly) view of biotech, IBB

The inverted chart puts it into perspective. Biotech has already reversed.

It would seem fitting as truth is hard to put down forever.

One can only hope the whole fake ‘speck’ narrative will be blown wide open … taking the entire sector down with it.

It may already be happening but in such slow (long term) motion that we’re not noticing it.

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech Breakdown

Biotech ETF, IBB looks ready to complete its breakout test and reverse to much lower levels.

There’s a lot going on in this sector.

At this juncture, IBB appears to be the overall downside leader.

The link to this video is the first of its kind. There’ll be more to follow.

Judging from the comments section of ZeroHedge, looks like everyone’s pretty much awake at this point.

Just in case, here are 25-quesitons that can be posed to those still asleep.

Pay special attention to Question No. 11. & No. 12.

At some point you would think it’s all going to bust wide open.

Moving on to the chart:

IBB’s been in a terminating wedge for over a year. There was a ‘throw-over’ in February. Next, was downside penetration of the lower boundary. Now, we’re in a test.

That test can still go higher to contact the boundary underside. However, as posted yesterday, we’re already positioned short (not advice, not a recommendation) at the 38.2%, contact and rejection.

From a fundamental perspective, all the good news is out. Probably the last of any ‘stimulus’ will be figuratively mailed out by the end of the month.

Bonds look to be forming a bottom and the dollar as well.

Even so, the higher interest rates are already having an effect as home buyers are backing off. Lumber prices remain at insane levels.

Positioning:

Last session, the firm’s accounts went short biotech. Pre-market action in LABD shows a slightly lower open (higher for IBB).

The stops for both BIS and LABD have been provided in the last update. Be aware, the stop is loosely based on the tracking fund IBB.

If IBB posts a high above 154.60, its likely to attempt a 50% retrace.

One caveat:

There’s probably an accumulation of short stops (like ours) at the 154.60, high.

If there are enough, the market will automatically go one, or two ticks higher (154.62), to clear them out.

We’ll watch for that and adjust our stops accordingly. If this happens, it’s likely to be within the first 90-minutes of trade.

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech (IBB) Action Like AMT

In price action very similar to AMT before its reversal, IBB looks ready to move decisively lower. Early session hit 38.2% retrace and now, test action (higher) looks weak.

Markets are fractal. Price action repeats itself at various time-frames.

Expectation is that IBB will continue lower from here just as was the case with AMT.

The difference is, since we’re dealing with an hourly time frame instead of daily, price action is faster.

All accounts have been cleared of positions except for being short biotech.

Positions are as follows (not advice, not a recommendation):

LABD: Entry, 19.976, Stop 19.52

BIS: Entry 22.32, Stop 21.75

There are a number of problems for biotech hovering the background that could blow the lid off the ‘planned event’ of the past year.

More information to be provided in a subsequent update

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.